Industry reports and press releases indicate that semaglutide and tirzepatide together contribute billions in quarterly revenue, placing them in the top tier of global pharmaceutical sales
Predicting the sequence specificities of DNA-and RNA-binding proteins by deep learning
Delivering over $3.3 billion * in gross savings related to Humira (adalimumab) GLP-1s: More options, more demand, more challenges GLP1s, specifically those approved for weight management, have rapidly changed the pharmacy benefit landscape
Semaglutide increases glucose-dependent insulin secretion in response to elevated glucose levels after meals, reduces glucagon release, and slows down gastric emptying, leading to appetite suppression for weight management
Cymbiotika Liposomal Glutathione delivers one of the body's most essential antioxidants in a highly absorbable liposomal format